Navigation Links
Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
Date:7/8/2009

CAMBRIDGE, England, July 8 /PRNewswire/ -- Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.

"We are extremely pleased with the outcome of this initial clinical study with FX125L," said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. "The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L."

About Funxional Therapeutics Ltd.

Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge.

For more information about FXT, please visit our web site (http://www.funxionaltherapeutics.com) or contact us by e-mail (info@funxionaltherapeutics.com).

About BSCIs

BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases.

BSCIs are one of the three proprietary technology platforms in FXT's portfolio all of which originated in the University of Cambridge. BSCIs were discovered based upon a strategy that exploits functional screening to develop novel new classes of drugs. FX125L is the lead drug candidate in this novel class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents.

For enquiries regarding this press release, please contact Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics, at +44-1223-451095.


'/>"/>
SOURCE Funxional Therapeutics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
4. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
5. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
6. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
9. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
10. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... California (PRWEB) , ... April 25, 2017 , ... ... Intelligence (AI), leading supplier of Common Lisp (CL) development tools, and market leader ... , which includes key performance enhancements now available within the most effective system ...
(Date:4/25/2017)... April 25, 2017 Providence ... licensed its novel immune-modulating technology to an undisclosed global ... allergy. Tregitopes, pronounced T·rej·itopes, are a ... by EpiVax CEO Annie De Groot ... immunoglobulin G, an autoimmune disease therapy, Tregitopes are ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Partners.     , Covalent’s Analytical Services unit provides high-quality data to clients, ... within 24 hours of receipt. There are no price premiums, and customers are ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... denaturation in a cellular milieu; however, the broad application of this cellular target ... platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for ...
Breaking Biology Technology:
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), ... published by MarketsandMarkets, the market is expected to be worth USD 18.98 billion ... Continue Reading ... ...      (Logo: ...
Breaking Biology News(10 mins):